Literature DB >> 29127441

Verification of a genetic locus for methamphetamine intake and the impact of morphine.

Emily C Eastwood1,2,3, Amy J Eshleman1,4,5, Aaron Janowsky1,2,4,5, Tamara J Phillips6,7,8,9.   

Abstract

A quantitative trait locus (QTL) on proximal chromosome (Chr) 10 accounts for > 50% of the genetic variance in methamphetamine (MA) intake in mice selectively bred for high (MAHDR) and low (MALDR) voluntary MA drinking. The µ-opioid receptor (MOP-r) gene, Oprm1, resides at the proximal end of Chr 10, and buprenorphine reduces MA intake in MAHDR mice. However, this drug has only partial agonist effects at MOP-r. We investigated the impact of a full MOP-r agonist, morphine, on MA intake and saccharin intake, measured MOP-r density and affinity in several brain regions of the MA drinking lines and their C57BL/6J (B6) and DBA/2J (D2) progenitor strains, and measured MA intake in two congenic strains of mice to verify the QTL and reduce the QTL interval. Morphine reduced MA intake in the MAHDR line, but also reduced saccharin and total fluid intake. MOP-r density was lower in the medial prefrontal cortex of MAHDR, compared to MALDR, mice, but not in the nucleus accumbens or ventral midbrain; there were no MOP-r affinity differences. No significant differences in MOP-r density or affinity were found between the progenitor strains. Finally, Chr 10 congenic results were consistent with previous data suggesting that Oprm1 is not a quantitative trait gene, but is impacted by the gene network underlying MA intake. Stimulation of opioid pathways by a full agonist can reduce MA intake, but may also non-specifically affect consummatory behavior; thus, a partial agonist may be a better pharmacotherapeutic.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29127441      PMCID: PMC5889309          DOI: 10.1007/s00335-017-9724-5

Source DB:  PubMed          Journal:  Mamm Genome        ISSN: 0938-8990            Impact factor:   2.957


  44 in total

1.  Genetically correlated effects of selective breeding for high and low methamphetamine consumption.

Authors:  J M Wheeler; C Reed; S Burkhart-Kasch; N Li; C L Cunningham; A Janowsky; F H Franken; K M Wiren; J G Hashimoto; A C Scibelli; T J Phillips
Journal:  Genes Brain Behav       Date:  2009-07-21       Impact factor: 3.449

2.  Profound reduction in sensitivity to the aversive effects of methamphetamine in mice bred for high methamphetamine intake.

Authors:  Shkelzen Shabani; Carrie S McKinnon; Christopher L Cunningham; Tamara J Phillips
Journal:  Neuropharmacology       Date:  2011-11-18       Impact factor: 5.250

3.  The effect of intrinsic efficacy on opioid tolerance.

Authors:  A Duttaroy; B C Yoburn
Journal:  Anesthesiology       Date:  1995-05       Impact factor: 7.892

4.  Clinical actions of fentanyl and buprenorphine. The significance of receptor binding.

Authors:  R A Boas; J W Villiger
Journal:  Br J Anaesth       Date:  1985-02       Impact factor: 9.166

5.  Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence.

Authors:  Nitya Jayaram-Lindström; Maija Konstenius; Staffan Eksborg; Olof Beck; Anders Hammarberg; Johan Franck
Journal:  Neuropsychopharmacology       Date:  2007-10-24       Impact factor: 7.853

6.  Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors.

Authors:  Kabirullah Lutfy; Shoshana Eitan; Camron D Bryant; Yu C Yang; Nazli Saliminejad; Wendy Walwyn; Brigitte L Kieffer; Hiroshi Takeshima; F Ivy Carroll; Nigel T Maidment; Christopher J Evans
Journal:  J Neurosci       Date:  2003-11-12       Impact factor: 6.167

7.  A high-resolution single nucleotide polymorphism genetic map of the mouse genome.

Authors:  Sagiv Shifman; Jordana Tzenova Bell; Richard R Copley; Martin S Taylor; Robert W Williams; Richard Mott; Jonathan Flint
Journal:  PLoS Biol       Date:  2006-11       Impact factor: 8.029

8.  A Mouse Model for Binge-Level Methamphetamine Use.

Authors:  Shkelzen Shabani; Sydney K Houlton; Laura Hellmuth; Erika Mojica; John R K Mootz; Zhen Zhu; Cheryl Reed; Tamara J Phillips
Journal:  Front Neurosci       Date:  2016-11-02       Impact factor: 4.677

9.  Naltrexone modulates dopamine release following chronic, but not acute amphetamine administration: a translational study.

Authors:  N Jayaram-Lindström; J Guterstam; J Häggkvist; M Ericson; T Malmlöf; B Schilström; C Halldin; S Cervenka; T Saijo; A-L Nordström; J Franck
Journal:  Transl Psychiatry       Date:  2017-04-25       Impact factor: 6.222

Review 10.  An animal model of differential genetic risk for methamphetamine intake.

Authors:  Tamara J Phillips; Shkelzen Shabani
Journal:  Front Neurosci       Date:  2015-09-23       Impact factor: 4.677

View more
  6 in total

1.  Differential genetic risk for methamphetamine intake confers differential sensitivity to the temperature-altering effects of other addictive drugs.

Authors:  John R K Mootz; Nicholas B Miner; Tamara J Phillips
Journal:  Genes Brain Behav       Date:  2020-01-15       Impact factor: 3.449

2.  Non-genetic factors that influence methamphetamine intake in a genetic model of differential methamphetamine consumption.

Authors:  A M Stafford; C Reed; T J Phillips
Journal:  Psychopharmacology (Berl)       Date:  2020-08-24       Impact factor: 4.530

3.  Depression-like symptoms of withdrawal in a genetic mouse model of binge methamphetamine intake.

Authors:  Shkelzen Shabani; Bryan Schmidt; Bikalpa Ghimire; Sydney K Houlton; Laura Hellmuth; Erika Mojica; Tamara J Phillips
Journal:  Genes Brain Behav       Date:  2018-11-26       Impact factor: 3.449

4.  Taar1 gene variants have a causal role in methamphetamine intake and response and interact with Oprm1.

Authors:  Alexandra M Stafford; Cheryl Reed; Harue Baba; Nicole Ar Walter; John Rk Mootz; Robert W Williams; Kim A Neve; Lev M Fedorov; Aaron J Janowsky; Tamara J Phillips
Journal:  Elife       Date:  2019-07-09       Impact factor: 8.140

5.  Regional Analysis of the Brain Transcriptome in Mice Bred for High and Low Methamphetamine Consumption.

Authors:  Robert Hitzemann; Ovidiu D Iancu; Cheryl Reed; Harue Baba; Denesa R Lockwood; Tamara J Phillips
Journal:  Brain Sci       Date:  2019-06-30

6.  Confirmation of a Causal Taar1 Allelic Variant in Addiction-Relevant Methamphetamine Behaviors.

Authors:  Tamara J Phillips; Tyler Roy; Sara J Aldrich; Harue Baba; Jason Erk; John R K Mootz; Cheryl Reed; Elissa J Chesler
Journal:  Front Psychiatry       Date:  2021-08-26       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.